Stephens initiated coverage of Arvinas (ARVN) with an Overweight rating and $55 price target. The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation, or ...
Arvinas, Inc. is a clinical-stage biotech firm focusing on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. We believe Arvinas is a short due to weak ...
Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...
Arvinas plans to reduce its workforce by 15% as it plans to out-license the commercial rights for its breast cancer drug vepdegestrant. Arvinas and Pfizer have been working to develop vepdegestrant, ...
The findings were presented in Chicago at the annual meeting of the American Society of Clinical Oncology and published in The New England Journal of Medicine. The trial found the experimental drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback